GEN Exclusives

More »

GEN News Highlights

More »
Sep 28, 2006

Xoma to Supply Aveo with anti-HGF Antibody

  • Xoma and Aveo Pharmaceuticals reported a $6-million agreement under which Xoma will manufacture and supply AV-299, Aveo’s anti-HGF antibody, to support early clinical trials. The companies also announced that Xoma has successfully completed the Human Engineering™ (HE™) of AV-299.

    For work conducted and licenses granted, Xoma received an upfront license fee and is eligible for development milestones and royalty payments on sales of AV-299. Aveo retains all development and commercialization rights to AV-299.

    Under the supply agreement, Xoma will create AV-299 production cell lines and conduct process and assay development, as well as cGMP manufacturing activities in support of Aveo’s IND filing and early clinical trials.

    In April, Xoma and Aveo announced an agreement under which Xoma would use its HE technology to humanize AV-299. Xoma created four Human Engineered versions of the original AV-299. From these four versions, Aveo selected one as its lead development candidate.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?